Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease, which
causes progressive cough, exertional dyspnea, impaired quality of life and death …

CONCLUSIONS• Bexotegrast was well tolerated across all dose groups over 12 weeks of
treatment; most TEAEs were mild or moderate in severity, with no drug-related SAEs. There …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking
effective treatment. Objectives: To determine the effects of bosentan on exercise capacity …

Idiopathic pulmonary fibrosis (IPF) is a quality-of-life-altering and life-shortening lung
disease manifested by physiologic restriction, hypoxemia and progressive shortness of …

Results: In preliminary, blinded analysis of baseline data from all randomized patients, the
mean age was 63.6 years (standard deviation [SD], 8.6). In total, 429 patients (69.6%) were …

Rationale: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend
to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and …

Introduction Components of the hedgehog signaling pathway are upregulated in patients
with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog …

Time flies: almost a decade ago the results of the INPULSIS (Safety and Efficacy of BIBF
1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients) and ASCEND (Efficacy and …

Despite a new drug approved in Europe, Japan and Canada, pulmonologists have little to
offer patients with idiopathic pulmonary fibrosis (IPF). InterMune's Esbriet (pirfenidone) …

Introduction Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive
fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However …